<DOC>
	<DOCNO>NCT00568594</DOCNO>
	<brief_summary>The purpose study determine : ( 1 ) safety pharmacokinetics APL180 administer single intravenous infusion healthy volunteer , ( 2 ) safety , pharmacokinetics pharmacodynamics single multiple daily intravenous infusion APL018 patient CHD</brief_summary>
	<brief_title>Safety Efficacy APL180 Healthy Volunteers Patients With Coronary Heart Disease ( CHD )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Male female healthy volunteer ( age 1855 year ) patient CHD ( age 18 75 year ) stable statin therapy least 8 week , normal liver kidney function . Women postmenopausal , surgically sterile , practice effective contraception . Additional birth control detail provide screen . Body mass index ( BMI ) must within range 20 35 CHD patient CHD equivalent . Clinical CHD : Myocardial infarction ( MI ) , angina , revascularization ( e.g . CABG , stent ) least 6 month prior inclusion CHD equivalent : symptomatic carotid artery disease ( e.g . transient ischemic attack stroke carotid origin ) peripheral artery disease abdominal aortic aneurysm Diabetes Mellitus ( HbA1c ≤9 ) 20 % 10 year risk CHD ( Framingham point score : ≥16 ( men ) , ≥23 ( woman ) ) Other clinical form atherosclerotic disease include &gt; 50 percent stenosis angiography ultrasound Male subject , sexually active , use one form highly effective contraception ( e.g . condom ) Exclusion Criteria healthy volunteer patient : Smokers ( use tobacco product previous 3 month ) . Smokers report cigarette use 10 cigarette per day urinary cotinine level great 500 ng/ml . Pregnancy . Use prescription drug within four ( 4 ) week prior dose , overthecounter ( OTC ) medication ( vitamin , herbal supplement , dietary supplement ) within two ( 2 ) week prior dose . Significant illness within two week prior dose . Significant illness within two week prior dose . A past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome . History clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug allergic reaction prior receipt protein therapy vaccine . Presence NYHA Class III IV CHF unstable angina pectoris . MI within angioplasty ( include stenting ) , acute coronary syndrome ( ACS ) , unstable angina arterial embolic disease within 6 month prior dose . Use certain medication prohibit protocol . Uncontrolled diabetes ( HbA1c &gt; 9 ) . Uncontrolled hypertension ( Systolic BP &gt; 160 mm Hg and/or Diastolic BP &gt; 100 mmHg two consecutive measurement ) . Liver kidney disease confirm abnormal lab value function . Serum creatine kinase CK ( CPK ) total &gt; 2x . CHD equivalent patient history early positive exercise stress test . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Apolipoprotein A-I ,</keyword>
	<keyword>Atherosclerosis ,</keyword>
	<keyword>HDL ,</keyword>
	<keyword>Inflammation ,</keyword>
</DOC>